These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25016505)

  • 1. Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials.
    Chen J; Shen P; Zhang XC; Zhao MD; Zhang XG; Yang L
    Clin Ther; 2014 Aug; 36(8):1253-63. PubMed ID: 25016505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer.
    Yi L; Zhang W; Zhang H; Shen J; Zou J; Luo P; Zhang J
    Drug Des Devel Ther; 2018; 12():2455-2466. PubMed ID: 30122902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials.
    Zhou YY; Hu ZG; Zeng FJ; Han J
    PLoS One; 2016; 11(3):e0151939. PubMed ID: 27007231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
    Santos FN; Castria TB; Cruz MR; Riera R
    Sao Paulo Med J; 2016; 134(5):465-466. PubMed ID: 27901246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer.
    Wang S; Wang Q; Tian J; Zhou Z; Jiao L; Fu Y; Chen S; Zhang J; Xu L
    J Int Med Res; 2015 Dec; 43(6):727-37. PubMed ID: 26438014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.
    Li X; Wang H; Lin W; Xu Q
    Curr Med Res Opin; 2014 Nov; 30(11):2295-304. PubMed ID: 24701984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
    J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
    Liang RF; Zheng LL
    Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007744. PubMed ID: 25340915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials.
    Liu CQ; Tian D; Wang N; Meng XP; Yang JD; Li HW; Zhao N; Zhao S; Liao F; Cui Y
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e81-e87. PubMed ID: 29071806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
    Shi L; Tang J; Tong L; Liu Z
    Lung Cancer; 2014 Feb; 83(2):231-9. PubMed ID: 24332320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
    Zhong A; Xiong X; Shi M; Xu H
    Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines.
    Wang J; Li G; Yu L; Mo T; Wu Q; Zhou Z
    J Ethnopharmacol; 2018 Jul; 221():137-150. PubMed ID: 29655852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
    Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
    Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis.
    Luo L; Hu Q; Jiang JX; Yang X; Dinglin XX; Lin X; Yao HR
    Asia Pac J Clin Oncol; 2015 Sep; 11(3):253-61. PubMed ID: 25866140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Zhang M; Guo H; Zhao S; Wang Y; Yang M; Yu J; Yan Y; Wang Y
    Oncotarget; 2016 Jun; 7(26):39823-39833. PubMed ID: 27223081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
    Hong C; Mei T; Wang J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with first-generation EGFR-TKI in treating advanced non-small cell lung cancer].
    He W; Cheng M
    Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2591-2598. PubMed ID: 28840704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.